Description of drug utilization and assessment of impact of Saxagliptin on health status of patients with type 2 diabetes in France - DIAPAZON

Study identifier:CV181-148

ClinicalTrials.gov identifier:NCT01552005

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Description of drug utilization and assessment of impact of Saxagliptin on health status of patients with type 2 diabetes in France

Medical condition

Type 2 diabetes mellitus (T2D)

Phase

-

Healthy volunteers

No

Study drug

Saxagliptin

Sex

All

Actual Enrollment

1000

Study type

Observational

Age

18 Years +

Date

Study Start Date: 01 May 2012
Primary Completion Date: 01 Jun 2015
Study Completion Date: 01 Jun 2015

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Jun 2016 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria